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psoriasis were as follows: 13%were currently taking a biologic, 42%would consider
taking a biologic, 17% had previously taken a biologic, and 24% would not consider
taking a biologic. Hierarchical and non-hierarchical cluster analyses were applied
to themoment-to-moment affect traces that identified four unique patient clusters
(# 1-4). MDA was used to identify the five most impactful time periods within the
focus group audio segments. Cluster composition profiles were identified based
upon demographic information and patient responses to behavioral and attitudi-
nal questions. CONCLUSIONS: Understanding complex patient perspectives on
coping with disease is essential for delivering appropriate treatments over the
lifelong course of psoriasis. This novel methodology begins to bridge this knowl-
edge gap in understanding the patient-centered view of psoriasis. Furthermore, it
improves the likelihood of recommending treatments in alignment with the pa-
tient’s needs to improve health-related quality-of-life, productivity, and well-be-
ing.
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OBJECTIVES: Currently in Brazil’s public healthcare, patients with psoriasis who
fail the available treatment options (phototherapy, methotrexate, acitretin and
cyclosporin) due to any cause, are experiencing a medical unmet need. This study
is aimed to assess comorbidity, quality of life (QoL), work/productivity loss (WPL),
and medical resource utilization in patients diagnosed with psoriasis (PdwP) in
Brazil. METHODS: A total of 12,000 individuals’ (age 18) self-reported data were
collected from2011National Health andWellness Survey (NHWS) in Brazil, a cross-
sectional representative sample of the adult population. QoL was measured by the
physical component score (PCS) and mental component score (MCS) of the Short
Form-12 (SF-12). WPL wasmeasured by the validatedWork Productivity and Activ-
ity Impairment instrument. Medical resource utilization was measured by health
care provider utilization, emergency room visits and hospitalization in the past 6
months. RESULTS: Of the 12,000 respondents, 205 (1.3%) were patients diagnosed
with psoriasis (PdwP) (53.0% women). Mean age was 40.2. Higher percentage of
co-morbidities was found among PdwP compared to patients not diagnosed with
psoriasis (PndP): headache (71% vs. 54%), sleep difficulties (50% vs.24%), anxiety
(50% vs.33%), insomnia (46% vs.22%), pain (42% vs.23%), skin allergies (40% vs.17%),
migraine (40%vs.20%), Heartburn (38% vs.23%) hay fever (37% vs.15%), nasal aller-
gies (33% vs.21%), depression (33% vs.16%), rhinitis (32%vs.11%), high blood pres-
sure (29% vs.16%), gingivitis (22%vs.6%), nail fungus (20%vs.7% ), dry eye (20%
vs.5%), anemia (19%vs.6%), diabetes type 1 or 2 (19%vs.4%). PdwPhad a lowermean
PCS (45.8 vs. 49.7) and MCS (42.3 vs.47.0), more visiting health practitioners (87.0%
vs.76.0%), emergency room visits (36.0%vs.22.0%), and hospitalizations for a med-
ical condition (21.0% vs.10.0%) over the past 6months compared to the PndP group.
Furthermore, PdwP reported higher presenteeism (30.4% vs.14.8%), work produc-
tivity loss (34.0% vs 18.9%) and activity impairment (36.5% vs.20.9%) compared to
the PndP group. All mentioned differences were statistically significant at p0.05.
CONCLUSIONS: From Brazilian NHWS results, PdwP suffer from impairment in
QoL, WPL, and more co-morbidities.
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OBJECTIVES: To elicit modal salient behavioral beliefs, normative referents and
control beliefs of pharmacists regarding their intention to utilize online accessible
prescription drug monitoring program (PDMP) data when the validity of the pre-
scription or patient need is in question. METHODS: One hour focus groups were
conducted with a convenience sample of central Texas community pharmacists
with varied backgrounds and experiences. The theory of planned behavior was
used as the theoretical framework for the focus group guide, which consisted of
nine open-endedquestions to capture PDMPadvantages/disadvantages, important
influencers of utilization, and perceived facilitators or barriers. Content analysis
was performed on participants’ written responses to questions and focus groups’
transcripts. RESULTS: Three focus groups (Total N  23) were conducted. Nine
behavioral beliefs, eight normative referents and eight control beliefs were identi-
fied from the focus groups. Regarding advantages/disadvantages, pharmacists
most frequently mentioned that PDMP utilization would ensure appropriate con-
trolled medication therapy and prevent diversion. However, pharmacists were
fearful of potential increased liability as a result of having access to patients’ con-
trolled medication data. Important individuals or groups that pharmacists identi-
fied as influential to their decision to utilize PDMP data were regulatory agencies
(e.g., board of pharmacy), prescribers and pharmacy employers. The most impor-
tant belief that would facilitate PDMP utilization was interfacing the PDMP data-
base with their existing pharmacy software. The most frequently mentioned bar-
rier was lack of time to access data.CONCLUSIONS: The identification of items that
may influence pharmacists’ utilization of PDMP data when dispensing controlled
medications may be helpful to PDMP administrators’ implementation of online
accessible PDMPs. Increased utilization of PDMPs by pharmacists may lead to a
decrease in morbidity and mortality associated with controlled medication ther-
apy.
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OBJECTIVES: Purdue implemented a Risk Evaluation and Mitigation Strategy
(REMS) for Butrans (buprenorphine) Transdermal System that included distribu-
tion of a printed REMS Training in December 2010 to prescribers of extended re-
lease/long acting opioids to inform them on the risks and safe use of Butrans.
Prescribers who completed the training were asked to return a signed form with a
short post-test evaluation attached. We report on the results of the post-test eval-
uation by prescribers who completed the training between December 2010 and
February 2011. METHODS: The training guide was distributed to prescribers via
paper mail and field sales force in December 2010. The educational confirmation
form included 7 multiple choice questions with 26 response items measuring un-
derstanding of appropriate indication, dosing strength, storage and the risk factors
and signs of overdose, abuse and misuse. A multiple linear regression model was
computed to determine the mean total score and factors affecting it. RESULTS: A
total of 502 prescribers returned the formwhich included 36% general practitioners
and 64% specialists. The average score for correctly answering all the items was
97%. Average total score did not vary between general practitioners and specialists.
Prescribers scored relatively lower on items that individuals with a family history
of substance abuse are at increased risk of opioid abuse (82%) and individuals with
mental illness are at increased risk for opioid abuse (76%). CONCLUSIONS: Pre-
scribers completing the REMS training had high levels of understanding of the core
messages of the Butrans REMS; however, lower knowledge levels that mental ill-
ness and family history increase the risk of opioid abuse were identified. Another
survey of a random sample of Butrans prescribers from around the United States is
in progress.
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OBJECTIVES: Recent evidence suggests a higher risk of diabetes following smoking
cessation possibly related to the expectedweight gain. Quitting smoking, however,
remains recommended. The objective was to examine differences of smoking ces-
sation medication prescribing among smokers with different body weight levels
using theHealth andNutritional Examination Survey (NHANES) data.METHODS:A
retrospective cross-sectional study was conducted using the NHANES data from
1999 to 2008. The study included adults aged 18 yearswho self-reported currently
using tobacco. The outcome variable was receiving a cessationmedication (Bupro-
pion or Varenicline) vs. not. The independent variables included body mass index
(BMI), gender, age, race, education, marital status, family income, insurance type,
poverty income ratio (PIR), and health status. Multivariate logistic regression anal-
yses were conducted to assess the association between the main independent
variable (BMI) as well as socio-demographic and general health status characteris-
tics with the outcome variable. RESULTS: A total of 7743 adult smokers were in-
cluded. Among normal weight smokers, 2.72% were prescribed cessation medica-
tion, while 1.57% and 2.54% among overweight and obese smokers were prescribed
cessation medication, respectively. Logistic regression results showed that smok-
ers who were overweight were less likely to be prescribed cessation medications
than thosewithnormalweight (OR: 0.441, 95%CI: 0.212-0.915).Male smokers,white
race, having government insurance, college degree or above, PIR above average,
were significant factors of receiving a cessation medication. CONCLUSIONS: The
study documented a lower rate of smoking cessation medication use among over-
weight smokers compared to normal weight smokers. Whether this finding is re-
lated to physician or patient preferences remains uncertain. Future studies should
investigate the reasons for this discrepancy and develop effective interventions to
aid overweight smokers in quitting.
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OBJECTIVES: To examine differences in cessation medication prescribing among
smokers with different body weight levels using the National Ambulatory Medical
Care Survey (NAMCS) data. METHODS: A retrospective cross-sectional study was
conducted using the NAMCS data from 2005 to 2008. The study included visits with
smokers aged  18 and self-reported current tobacco use. The outcome variable
was being prescribed a cessation medication (Bupropion or Varenicline) vs. not.
The independent variables included body mass index (BMI), gender, age, race, ed-
ucation, insurance type, tobacco counseling, and health status. BMI splines were
used to describe different body levels. The knots of the BMI spline included normal,
overweight, obesity class I, II and III. Multivariate logistic regression analyses were
conducted to assess the association between the main independent variable of
BMI, as BMI splines in one model and a categorical variable in another model, as
well as socio-demographic and general health status characteristics with the out-
come variable. RESULTS: A total of 11,829 adult smoker visits were included.
Among normal weight visits, 6.28% had cessation medication prescriptions, while
4.70% and 3.89% among overweight and obese visits respectively had prescriptions.
Logistic regression showed that overweight (OR: 0.589, 95% CI: 0.351 – 0.987) and
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